Myasthenia gravis is an autoimmune disorder where antibodies against the nicotinic Ach receptor resulting in impaired transmission at the NM junction. A number of drugs have been reported to cause neuromuscular blockade and/or to increase weakness in myasthenia gravis. We report a case of myasthenia gravis in which the calcium channel blocker-nifedipine caused the worsening of the symptoms.

Plasmapheresis means elimination of plasma and replacement of it with other liquids. Effect of this treatment is confirmed in more than 50 diseases like myasthenia gravis, Guillain-Barre syndrome and TTP. This cross sectional study was done on 25 myasthenia gravis patients referred to Shahid Sadoughi hospital, Yazd, Iran 2004-2007. We report 22 myasthenia gravis patients' response to plasmapher...

The history of the development of knowledge of myasthenia gravis is reviewed. Clinical profiles of the immune and non-immune mediated forms of myasthenia are discussed. The current theory of pathogenesis is reviewed. Tests used to diagnose myasthenia gravis, and their comparative diagnostic yields are presented. Past and current modalities of treatment are reviewed. Future therapeutic stra...

myasthenia crisis is the most dangerous complication of myasthenia gravis. we report one case in which a continuous infusion of pyridostigmine resulted in successful management of myasthenia exacerbation in a 50 year old myasthenic female following thymectomy.

Myasthenia gravis is an autoimmune disease caused, in most cases, by antibodies attaching to the acetylcholine receptor. Some myasthenia gravis patients have antibodies that bind in a cross-striational pattern to skeletal and heart muscle tissue sections (striational antibodies). These antibodies react with epitopes on the muscle proteins titin and ryanodine receptor, are found mainly in sera o...

Myasthenia gravis is a disorder of impaired neuromuscular transmission resulting in weakness and abnormal fatigability on exertion, improved by anti-acetyl cholinesterase drugs. A number of drugs are known to exacerbate myasthenia gravis or interfere with neuromuscular transmission. We report a case of D-penicillamine induced myasthenia gravis who developed ptosis, diplopia and easy fatigabilit...

About 5-10% of patients with myasthenia gravis concomitantly have other autoimmune diseases. However, the coexistence of myasthenia gravis and pernicious anemia is rare. Here, we report a 73-year-old Taiwanese woman who developed myasthenia gravis 5 months after the onset of pernicious anemia. Her myasthenic and pernicious anemia symptoms markedly improved after pyridostigmine, prednisolone and...

BACKGROUND There are only rare reports of myasthenia gravis complicating human immunodeficiency virus infection. The role of immunomodulatory therapy is unknown. METHODS Case report and literature review. RESULTS The diagnosis of human immunodeficiency virus infection followed that of myasthenia gravis in a 35-year-old man. Clinical and electrophysiological features were diagnostic of gener...

introduction:yasthenia gravis is an autoimmune disorder resulting from a decreased number of active acetylcholine receptors at the neuromuscular junction. thymectomy is one of its current treatments. due to sensitivity of myasthenic patients to non-depolarizing muscle relaxants and also the interaction of this medication with anti-cholinestrase drugs, determining the dosage of non-depolarizing ...

The mechanisms that underlie the development and maintenance of autoimmunity in myasthenia gravis are poorly understood. In this investigation, we evaluate the role of survivin, a member of the inhibitor of apoptosis protein family, in humans and in two animal models. We identified survivin expression in cells with B lymphocyte and plasma cells markers, and in the thymuses of patients with myas...